Cellyan Biotechnology (HKPD) Non-Current Debt (2024 - 2025)
Cellyan Biotechnology (HKPD) posted quarterly Non-Current Debt of $1.3 million for Q3 2025, up 32.71% year-over-year from $1.0 million in Q3 2024, and down 11.25% quarter-over-quarter from $1.5 million in Q1 2025.
Cellyan Biotechnology (HKPD) Non-Current Debt (2024 - 2025) Analysis & Trends
Cellyan Biotechnology (HKPD) has reported Non-Current Debt for 2 consecutive years, with $1.3 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Non-Current Debt rose 32.71% year-over-year to $1.3 million; the TTM figure through Sep 2025 stood at $1.3 million (up 32.71% YoY), while the FY2025 annual figure was $1.5 million, up 34.35% from the prior year.
- Non-Current Debt retreated to $1.3 million in Q3 2025 per HKPD's latest filing, from $1.5 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $1.5 million in Q1 2025 and bottomed at $1.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Mckesson | 102.12 Bn | 96.96 Bn | 3.69 Bn | 9.73 Bn |
| 2 | Cencora | 61.67 Bn | 58.86 Bn | 3.61 Bn | 11.72 Bn |
| 3 | Cardinal Health | 54.51 Bn | 49.66 Bn | 2.56 Bn | 7.00 Bn |
| 4 | Henry Schein | 10.04 Bn | 9.88 Bn | 1.10 Bn | 2.30 Bn |
| 5 | Akso Health | 820.26 Mn | 820.04 Mn | - | - |
| 6 | Edap Tms | 157.38 Mn | 135.84 Mn | 7.34 Mn | 37.20 Mn |
| 7 | Accendra Health | 95.10 Mn | 87.45 Mn | 263.41 Mn | 1.72 Bn |
| 8 | 111 | 30.87 Mn | 109.39 Mn | 18.18 Mn | - |
| 9 | Cosmos Health | 13.30 Mn | 10.86 Mn | 1.51 Mn | 3.19 Mn |
| 10 | Cellyan Biotechnology | 6.38 Mn | 6.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.33 Mn |
| Mar 31, 2025 | 1.50 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | 1.12 Mn |